Skip to main content
SpringerLink
Log in

The abnormal expressions of tristetraprolin and the VEGF family in uraemic rats with peritoneal dialysis

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

The effect of peritoneal dialysis (PD) with high-glucose dialysis fluid on the VEGF family, tristetraprolin (TTP), angiogenesis and lymphangiogenesis was investigated. Forty male SD rats were randomised into five groups: normal group, sham operation group, uraemia group, PD 2-week group and PD4-week group. After 4 weeks of PD, microvessel density (MVD) and lymphatic vessel density (LVD) were measured. The expressions of both the VEGF family and TTP were detected. Compared with the normal group, the mRNA expression levels of the VEGF family were significantly increased in the uraemia group (P < 0.05), and also in the PD 2-week group and PD4-week group (P < 0.05) compared with uraemia group. The mRNAs of VEGF-A and VEGF-C in 4-week PD group likewise were significantly increased compared with the 2-week PD group. However, the mRNA expression of TTP was significantly decreased in the uraemia group compared with the normal group (P < 0.05), and also in the PD group compared with the uraemia group (P < 0.05). Compared with the normal group, the protein expressions of TTP were significantly decreased in the uraemia group (P < 0.05), and also in the PD group compared with the uraemia group (P < 0.05). Compared with the normal group, the MVD and LVD counts were gradually increased in the PD group, which was associated with PD time. In addition, the expression of TTP gradually decreased over PD time. High-glucose PD fluid and uraemic circumstance resulted in the abnormal expression of TTP and the VEGF family in a PD time-dependent manner; this may lead to UFF through angiogenesis and lymphangiogenesis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Roy H, Bhardwaj S, Yla-Herttuala S (2006) Biology of vascular endothelial growth factors. FEBS Lett 580:2879–2887

    Article  CAS  PubMed  Google Scholar 

  2. Karnezis T, Shayan R, Caesar C et al (2012) VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. Cancer Cell 21(2):181–195

    Article  CAS  PubMed  Google Scholar 

  3. Zweers MM, Struijk DG, Smit W, Krediet RT (2001) Vascular endothelial growth factor in peritoneal dialysis: a longitudinal follow-up. J Lab Clin Med 137:125–132

    Article  CAS  PubMed  Google Scholar 

  4. De Vriese AS, Tilton RG, Stephan CC, Lameire NH (2001) Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane. J Am Soc Nephrol 12:1734–1741

    PubMed  Google Scholar 

  5. Io H, Hamada C, Ro Y, Ito Y, Hirahara I, Tomino Y (2004) Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int 65(1927–1936):22

    Google Scholar 

  6. Carballo E, Lai WS, Blackshear PJ (1998) Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science 281:1001–1005

    Article  CAS  PubMed  Google Scholar 

  7. Carballo E, Lai WS, Blackshear PJ (2000) Evidence that tristetraprolin is a physiological regulator of granulocyte–macrophage colony-stimulating factor messenger RNA deadenylation and stability. Blood 95:1891–1899

    CAS  PubMed  Google Scholar 

  8. Lai WS, Carballo E, Strum JR, Kennington EA, Phillips RS, Blackshear PJ (1999) Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor alpha mRNA. Mol Cell Biol 19:4311–4323

    CAS  PubMed Central  PubMed  Google Scholar 

  9. Lai WS, Parker JS, Grissom SF, Stumpo DJ, Blackshear PJ (2006) Novel mRNA targets for tristetraprolin (TTP) identified by global analysis of stabilized transcripts in TTP-deficient fibroblasts. Mol Cell Biol 26:9196–9208

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Blackshear PJ (2002) Tristetraprolin and other CCCH tandem zinc-finger proteins in the regulation of mRNA turnover. Biochem Soc Trans 30(Pt 6):945–952

    CAS  PubMed  Google Scholar 

  11. Ogilvie RL, Abelson M, Hau HH, Vlasova I, Blackshear PJ, Bohjanen PR (2005) Tristetraprolin down-regulates IL-2 gene expression through AU-rich element-mediated mRNA decay. J Immunol 174:953–961

    Article  CAS  PubMed  Google Scholar 

  12. Ogilvie RL, Sternjohn JR, Rattenbacher B, Vlasova IA, Williams DA, Hau HH, Blackshear PJ, Bohjanen PR (2009) Tristetraprolin mediates interferon-gamma mRNA decay. J Biol Chem 284:11216–11223

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Bakheet T, Frevel M, Williams BR, Greer W, Khabar KS (2001) ARED: human AU-rich element-containing mRNA database reveals an unexpectedly diverse functional repertoire of encoded proteins. Nucleic Acids Res 29:246–254

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Lai WS, Blackshear PJ (2001) Interactions of CCCH zinc finger proteins with mRNA: tristetraprolin-mediated AU-rich elementdependent mRNA degradation can occur in the absence of a poly(A) tail. J Biol Chem 276:23144–23154

    Article  CAS  PubMed  Google Scholar 

  15. Sawaoka H, Dixon DA, Oates JA, Boutaud O (2003) Tristetraprolin binds to the 30-untranslated region of cyclooxygenase-2 mRNA. A polyadenylation variant in a cancer cell line lacks the binding site. J Biol Chem 278:13928–13935

    Article  CAS  PubMed  Google Scholar 

  16. Dixon DA (2004) Dysregulated post-transcriptional control of COX-2 gene expression in cancer. Curr Pharm Des 10:635–646

    Article  CAS  PubMed  Google Scholar 

  17. Weidner N (1995) Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 147(1):9–19

    CAS  PubMed Central  PubMed  Google Scholar 

  18. Weidner N, Semple JP, Welch WR et al (1991) Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324(1):1–8

    Article  CAS  PubMed  Google Scholar 

  19. Stacker SA, Williams RA, Achen MG (2004) Lymphangiogenic growth factors as markers of tumor metastasis. APMIS 112:539–549

    Article  CAS  PubMed  Google Scholar 

  20. Skobe M, Hawighorst T, Jackson DG et al (2001) Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7(2):192–198

    Article  CAS  PubMed  Google Scholar 

  21. Mandriota SJ, Jussila L, Jeltsch M et al (2001) Vascular endothelial growth factor-c-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 20(4):672–682

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Karpanen T, Alitalo K (2001) Lymphatic vessels as targets of tumor therapy. J Exp Med 194(6):F37–F42

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Liu T, Owen W, Yu YM et al (2000) Arginine, eitndline, and nilrie oxide melabolisin in end stage renal disease patients. Clin Invest 105(9):l217–l225

    Google Scholar 

  24. Ferrier ML, Combet S, van Landschoot M et al (2001) Inhibition of nitric oxide synthase reverses changes in peritoneal permeability in a rat model of acute peritonitis. Kidney Int 60(6):2343–2350

    Article  CAS  PubMed  Google Scholar 

  25. Devuyst O, Combet S, Cnops Y (2001) Regulation of NO synthase isoforms in the peritoneum: implications for ultrafiltration failure in peritoneal dialysis. Nephrol Dial Transpl 16(3):675–678

    Article  CAS  Google Scholar 

  26. Heimburger O, Waniewski J, Werynski A (1990) Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity Lindholm. Kidney Int. 38:495–506

    Article  CAS  PubMed  Google Scholar 

  27. Imholz AL, Koomen GC, Struijk DG (1993) Effect of dialysate osmolarity on the transport of low-molecular weight solutes and proteins during CAPD. Kidney Int. 43:1339–1346

    Article  CAS  PubMed  Google Scholar 

  28. Ho-dac-Pannekeet MM, Atasever B, Struijk DG (1997) Analysis of ultrafiltration failure in peritoneal dialysis patients by means of standard peritoneal permeability analysis. Dial Int. 17:144–150

    CAS  Google Scholar 

  29. Krediet RT (1999) The peritoneal membrane in chronic peritoneal dialysis. Kidney Int 55:341–356

    Article  CAS  PubMed  Google Scholar 

  30. Senger DR, Galli SJ, Dvorak AM (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983–985

    Article  CAS  PubMed  Google Scholar 

  31. Connolly DT, Olander JV, Heuvelman D (1989) Human vascular permeability factor. Isolation from U937 cells. Biol. Chem. 264:20017–20024

    CAS  Google Scholar 

  32. Hood JD, Meininger CJ, Ziche M, Granger HJ (1998) VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 274:H1054–H1058

    CAS  PubMed  Google Scholar 

  33. Ferrara N, Davis Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18:4–25

    Article  CAS  PubMed  Google Scholar 

  34. Devuyst O, Combet S, Pouthier D, Miyata T, Balligand JL, Glyoxalffin EJ (1998) Am. Soc. Nephrol. 9:191A

    Google Scholar 

  35. Niwa H, Takeda A, Wakai M (1998) Accelerated Formation of N ϵ-(carboxymethyl) Lysine, an advanced glycation end product, by glyoxal and 3-deoxyglucosone in cultured rat sensory neurons G. Sobue. Biochem Biophys Res Commun 248:93–97

    Article  CAS  PubMed  Google Scholar 

  36. Akhand AA, Kato M, Suzuki H (1999) Carbonyl compounds cross-link cellular proteins and activate protein-tyrosine kinase p60(c-Src) Cell. Biochem 72:1–7

    CAS  Google Scholar 

  37. Miyata T, Inagi R, Asahi K, Yamada Y, Horie K, Sakai H, Uchida K, Kurokawa K (1998) Generation of protein carbonyls by glycoxidation and lipoxidation reactions with autoxidation products of ascorbic acid and polyunsaturated fatty acids. FEBS Lett 437:24–28

    Article  CAS  PubMed  Google Scholar 

  38. Miyata T, Ueda Y, Yamada Y (1998) Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia. J Am Soc Nephrol 9:2349–2356

    CAS  PubMed  Google Scholar 

  39. Carballo E, Cao H, Lai WS, Kennington EA, Campbell D, Blackshear PJ (2001) Decreased sensitivity of tristetraprolin-deficient cells to p38 inhibitors suggests the involvement of tristetraprolin in the p38 signaling pathway. J Biol Chem 276:42580–42587

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  40. Mahtani KR, Brook M, Dean JL (2001) Mitogen-activated protein kinase p38 controls the expression and posttranslational modification of tristetraprolin, a regulator of tumor necrosis factor alpha mRNA stability. Mol Cell Biol 21:6461–6469

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  41. Johnson BA, Stehn JR, Yaffe MB, Blackwell TK (2002) Cytoplasmic localization of tristetraprolin involves 14-3-3-dependent and independent mechanisms. J Biol Chem 277:18029–18036

    Article  CAS  PubMed  Google Scholar 

  42. Chrestensen CA, Schroeder MJ, Shabanowitz J, Hunt DF, Pelo JW, Worthington MT, Sturgill TW (2004) MAPKAP kinase 2 phosphorylates tristetraprolin on in vivo sites including Ser178, a site required for 14-3-3 binding. J Biol Chem 279:10176–10184

    Article  CAS  PubMed  Google Scholar 

  43. Stoecklin G, Stubbs T, Kedersha N, Wax S, Rigby WF, Blackwell TK, Anderson P (2004) MK2-induced tristetraprolin:14-3-3 complexes prevent stress granule association and ARE-mRNA decay. EMBO J 23:1313–1324

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. Tsiani E, Lekas P, Fantus IG (2002) High glucose-enhanced activation of mesangial cell p38 MAPK by ET-1, ANG-2, and platelet-derived growth factor. Am J Physiol Endocrinol Metab  282:E161–E169

    Google Scholar 

  45. Jeon YJ, Kim BH, Kim S, Oh I, Lee S, Shin J, Kim TY (2013) Rhododendrin ameliorates skin inflammation through inhibition of NF-κB, MAPK, and PI3 K/Akt signaling. Eur J Pharmacol 714:7–14

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, No.1 Eastern Jianshe Road, Zhengzhou, 450052, Henan, China

    Jing Xiao, Huanhuan Gao, Yunfeng Jin, Zhihong Zhao, Jia Guo, Zhangsuo Liu & Zhanzheng Zhao

Authors
  1. Jing Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Huanhuan Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yunfeng Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhihong Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jia Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zhangsuo Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zhanzheng Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhanzheng Zhao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xiao, J., Gao, H., Jin, Y. et al. The abnormal expressions of tristetraprolin and the VEGF family in uraemic rats with peritoneal dialysis. Mol Cell Biochem 392, 229–238 (2014). https://doi.org/10.1007/s11010-014-2033-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11010-014-2033-3

Keywords

Search

Navigation